HTHideaki Tokiniwa

Hideaki Tokiniwa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hideaki Tokiniwa has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 June 2016
      • Vol. 36  (6) , 3019-22

    Clinicopathological Features of Cases with Primary Breast Cancer not Identified by 18F-FDG-PET.

    by Takaaki Fujii, Reina Yajima, Miki Tsuboi, Toru Higuchi, Sayaka Obayashi, Hideaki Tokiniwa, Rin Nagaoka, Daisuke Takata, Jun Horiguchi, Hiroyuki Kuwano

    Several studies have reported that high F18-fluorodeoxyglucose (FDG) uptake is predictive of poor prognosis and aggressive features in patients with breast cancer. While these studies evaluated the prognostic value for cases with high FDG uptake, they did not elucidate the meaning of FDG negativity in primary breast cancer. In this study, we evaluated the clinicopathological features of breast cancer cases without FDG uptake. We retrospectively investigated the cases of 219 consecutive patients with primary breast cancer who underwent FDG-positron emission tomography (PET) preoperatively. Among the 219 patients, 25 (11.4%) did not have FDG uptake in the tumor. The 219 cases with breast cancer were divided into two groups based on the presence of FDG uptake in the primary tumor. The present univariate analysis revealed that histology, small invasive tumor size, high estrogen receptor (ER) or progesterone receptor (PgR) expression, low nuclear grade and absence of lymph node metastasis were significantly associated with negative FDG uptake in the primary tumor. On the other hand, the size of ductal spread was not significantly different between the two groups. Multivariate analysis revealed that small-size tumor invasion and lower nuclear grade were statistically significant. Among the 25 cases without FDG uptake, there was no recurrent disease in spite of there being no case that underwent chemotherapy, while 4 cases among the 194 cases with FDG uptake had disease recurrence. Our findings imply that preoperative FDG negativity in primary breast cancer is effective in predicting better prognosis, but is less effective in predicting ductal spread. Cases without FDG uptake in the primary tumor may have a lower risk of recurrent disease and may be able to safely avoid adjuvant chemotherapy.


  • Open Access

    Bilateral Breast Cancer Detected by Screening Mammography

    by Sayaka Uchida, Jun Horiguchi, Mami Kikuchi, Daisuke Takata, Rin Nagaoka, Nawa Rokutanda, Ayako Sato, Hideaki Tokiniwa, Yukio Koibuchi, Tetsunari Oyama, et al.

    マンモグラフィ検診を契機に発見された両側乳癌症例について検討した。2007年1月から2012年5月までにマンモグラフィ検診を契機に発見された両側乳癌は8例であった。検診時に両側乳癌を指摘された症例は8例中3例だった。検診時には片側しか指摘されなかった5例のマンモグラフィをレトロスペクティブに検討した結果,対側乳癌を指摘できたのは1例のみであった。検診時には片側しか指摘されなかった5例の対側乳癌の発見契機は,CC撮影を加えて指摘された症例が1例,USで指摘された症例が2例,MRIで指摘された症例が2例であった。検診時に指摘されなかった乳癌の5例中3例は浸潤癌,2例は非浸潤癌であった。検診マンモグラフィで片側のみ要精査となった症例でも,対側に非浸潤癌だけでなく,小さな浸潤癌が発見されることもあり,対側乳房に関しても,USやMRIで詳細な検索を行う必要がある。

    • 1 September 2013
      • Vol. 40  (9) , 1175-80

    [Phase I study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer].

    by Jun Horiguchi, Daisuke Takata, Nana Rokutanda, Rin Nagaoka, Hideaki Tokiniwa, Hiroki Odawara, Mami Kikuchi, Ayako Sato, Izumi Takeyoshi

    S-1 is a novel oral anticancer agent consisting of tegafur, a prodrug of 5-fluorouracil, and 2 modulators. A phase I study of sequential S-1 and cyclophosphamide(CPA)therapy was conducted to determine the dose-limiting toxicities(DLTs)and recommended doses(RDs)in patients with metastatic or recurrent breast cancer(MBC). Patients with MBC received sequential S-1 and CPA. Chemotherapy consisted of administration of S-1 twice daily on days 1-14 at escalating doses of 40, 50, 65, and 80mg/m2/day and CPA at 100 mg/body/day on days 15-28. The schedule was repeated twice at a 4-week interval. The purposes of this study were to determine the RDs, safety, and efficacy of the regimen. A total of 12 patients were registered. No patients experienced DLTs, and the RDs of S-1 and CPA were 80mg/m2/day and 100 mg/body/day, respectively. The response rate was 50. 0%. In conclusion, sequential therapy with S-1 and CPA could be safely and effectively used for the treatment of MBC, and the RDs for this regimen were determined to be 80mg/m2/day for S-1 and 100 mg/m2/day for CPA.


  • Pure Laparoscopic Spleen-Preserving Distal Pancreatectomy for Pancreatic Tumor

    by Izumi Takeyoshi, Yutaka Sunose, Keitaro Hirai, Daisuke Yoshinari, Hiroomi Ogawa, Hiroshi Tsukagoshi, Norifumi Takahashi, Hotaka Yamazaki, Kengo Takahashi, Takamichi Igarashi, et al.

    • 1 September 2011
      • Vol. 31  (9) , 3041-6

    Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.

    by Jun Horiguchi, Tetsunari Oyama, Daisuke Takata, Nana Rokutanda, Rin Nagaoka, Hiroki Odawara, Hideaki Tokiniwa, Katsunori Tozuka, Mami Kikuchi, Ayako Sato, et al.

    Trastuzumab and various chemotherapy combinations have shown superior results in patients with primary and metastatic breast cancer. However, cardiotoxicity becomes a major adverse event when trastuzumab is used with anthracycline-containing regimens. The purpose of this study was to determine the clinical and pathological efficacy of neoadjuvant chemotherapy (NAC), using trastuzumab and chemotherapy, with or without anthracyclines, for patients with primary breast cancer and human epidermal growth factor receptor 2 (HER2-)-positive tumors. A retrospective analysis of 41 patients with stage II and III primary breast cancer and HER2-positive tumors treated with NAC was performed. NAC consisted of weekly paclitaxel plus trastuzumab with (PTA group, n=21) or without anthracycline (PT group, n=20). Patients in the PTA group received four courses of 5-fluorouracil, epirubicin, and cyclophosphamide every 3 weeks followed by concomitant 80 mg/m² paclitaxel and trastuzumab weekly for 12 weeks, and those in the PT group received four courses of 80 mg/m² paclitaxel weekly (days 1, 8, and 15) followed by a 1-week break and trastuzumab weekly (days 1, 8, 15, and 29). The median age of the patients was 50 years. Of 41 patients, 21 (51%) had a pathological complete response (pCR). Patients with clinical stage II cancer had a higher pCR rate compared with those with clinical stage III. Patients with estrogen receptor (ER)-negative tumors showed a trend toward a higher pCR rate. No significant difference was observed according age, clinical stage, ER status, clinical response, or pathological response between the PTA and the PT groups. The pCR rate of the PTA and the PT groups was 47.6% and 55.0%, respectively. No significant difference in disease-free survival was observed between the two groups at a median follow-up of 32 months. Trastuzumab-containing NAC is effective irrespective of anthracycline use for treating patients with primary breast cancer and HER2-positive tumors.


  • Open Access

    Papillary lesions of the breast diagnosed using core needle biopsies

    by Hideaki Tokiniwa, Jun Horiguchi, Daisuke Takata, Mami Kikuchi, Nana Rokutanda, Rin Nagaoka, Ayako Sato, Hiroki Odawara, Katsunori Tozuka, Tetsunari Oyama, et al.

    Papillary lesions of the breast include a broad spectrum of lesions, from benign papillomas to papillary carcinomas. It is difficult to determine whether a lesion is benign or malignant based on the fragmented material of a core needle biopsy (CNB). This study evaluated patients with papillary lesions examined using CNB. We retrospectively reviewed 31 papillary lesions diagnosed using CNB between 2004 and 2007. The clinical findings of benign and malignant papillary lesions were compared. The average patient age was 48.9 years. Twelve patients presented with a discharge and 10 patients presented with a lump. Eight patients were asymptomatic. The initial diagnoses by CNB of the 31 lesions were 25 intraductal papillomas, 4 intracystic papillomas and 2 adenomas. After CNB, excisional biopsies were performed in 23 patients and biopsies with a Mammotome® in 2 patients. Seven patients underwent regular follow-up. Five (16%) of the 31 patients with papillary lesions were ultimately diagnosed with breast cancer. The average distance from the nipple to a tumor diagnosed as malignant was 2.46 cm, which was longer than for a tumor diagnosed as benign. Ultimately, 5 papillary lesions (16%) were diagnosed as breast cancer. To avoid overlooking a malignancy, surgical excision is advantageous for papillary lesions, particularly those located far from the nipple.


  • Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer

    by Hideaki Tokiniwa, Jun Horiguchi, Daisuke Takata, Mami Kikuchi, Nana Rokutanda, Rin Nagaoka, Ayako Sato, Hiroki Odawara, Katsunori Tozuka, Tetsunari Oyama, et al.

    Topoisomerase II alpha (Topo IIa) is involved in DNA replication and is a molecular target for anthracycline-based chemotherapy. The Ki-67 labeling index (LI) is an evaluation of tumor cell proliferation. The objective of this study was to evaluate relationships among Topo IIa expression, the Ki-67 LI, and prognostic factors in estrogen receptor (ER)-positive, human epidermal growth factor type-2 (HER2)-negative breast cancer. Seventy-one patients were diagnosed with ER-positive, HER2-negative breast cancer between July 2003 and December 2004. Formalin-fixed, paraffin-embedded tumor specimens were stained for Topo IIa expression and Ki-67 LI. We investigated the correlation of the level of Topo IIa expression and the Ki-67 LI with clinical factors such as age, tumor size, progesterone receptor status, nodal status, nuclear grade, and lymphovascular invasion (LVI). Statistically significant differences were observed between Topo IIa overexpression, nuclear grade (p = 0.036), and LVI (p = 0.029). Topo IIa overexpression was statistically correlated with the Ki-67 LI (p < 0.0001). A statistically significant difference was observed between the Ki-67 LI and nuclear grade (p = 0.01). Survival analysis revealed the significant prognostic value of Ki-67 LI in patients with ER-positive, HER2-negative breast cancer (p = 0.003). Ki-67 LI is a strong prognostic factor in ER-positive HER2-negative breast cancer. Topo IIa overexpression was significantly correlated with the Ki-67 LI, nuclear grade, and LVI. These findings suggest use of Topo IIa expression as a proliferation marker and a prognostic factor in ER-positive, HER2-negative breast cancer.


    • 1 November 2008
      • Vol. 35  (11) , 1877-81

    [A phase I study of combination therapy with capecitabine and paclitaxel for patients with inoperable breast cancer or recurrent breast cancer].

    by Jun Horiguchi, Yukio Koibuchi, Nana Rokutanda, Rin Nagaoka, Mami Kikuchi, Ayako Sato, Hiroki Odawara, Yuko Ishikawa, Hideaki Tokiniwa, Yuichi Iino, et al.

    A dose-escalation study was conducted for patients with inoperable or recurrent breast cancer in order to determine the recommended dose (RD) of capecitabine combined with a fixed dose of weekly paclitaxel. Capecitabine was administered twice daily from day 1 through day 14 combined with paclitaxel given on days 1 and 8, every 21 days. Dose-limiting toxicities(DLT)were evaluated during the first two cycles. Three patients were recruited at one of two dose levels (capecitabine 1,255 mg/m2 or 1,657 mg/m2, paclitaxel 80 mg/m2). In this study, no DLT was seen in each level, and the RD of capecitabine was determined to be 1,657 mg/m2.

  • Open Access

    RETROPERITONEAL MYELOLIPOMA-A CASE REPORT-

    by Hideaki Tokiniwa, Susumu Kawate, Susumu Ohwada, Izumi Takeyoshi, Yutaka Sunose, Yasuo Morishita